Physicians' Academy for Cardiovascular Education

Targeting Lp(a) in CV risk reduction: where are we now?

Listen to the podcast
10' education - Oct. 5, 2022 - Pia Kamstrup, MD, PhD – Copenhagen, Denmark

Video navigation menu

  • What is Lp(a)? 00:31
  • Three key publications in the Lp(a) field 03:10
  • Lp(a)-associated risk is independent of other risk factors 05:11
  • High Lp(a) and risk of MI, calcific aortic valve stenosis, HF, ischemic stroke, PAD and mortality 06:34
  • Lp(a) levels and incident ASCVD across racial/ethnic subgroup 08:18
  • Conclusions 10:22


Show transcript

Educational information

This lecture by Pia Kamstrup was part of the EBAC-accredited symposium "Lp(a): from causality to therapy" held during the ESC congress 2022.


Pia Kamstrup, MD, PhD is Head of the Department of Clinical Biochemistry at the Copenhagen University Hospital – Herlev & Gentofte, Denmark.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by unrestricted educational grants from NewAmsterdam Pharma, Novartis, Sanofi and Roche Diagnostics.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: